[1] |
Negewo NA,Gibson PG,Mc Donald VM.COPD and its comorbidities:impact,measurement and mechanisms[J].Respirology,2015,20(8):1160-1171.
|
[2] |
Hillas G,Perlikos F,Tsiligianni I,et al.Managing comorbidities in COPD[J].Int J Chron Obstruct Pulmon Dis,2015,10:95-109.
|
[3] |
Mammen MJ,Sethi S.COPD and the microbiome[J].Respirology,2016,21(4):590-599.
|
[4] |
张伟,姚玉强,谷明明,等.COPD各时期的心肺组织病理及细胞超微结构观察[J].河北医药,2013,35(12):1767-1769.
|
[5] |
李永兰.沙美特罗/丙酸氟替卡松联合噻托溴铵治疗老年慢性阻塞性肺疾病的临床分析[J].中国医药科学,2016,6(14):69-72.
|
[6] |
Selzler AM,Wald J,Sedeno M,et al.Telehealth pulmonary rehabilitation:a review of the literature and an example of a nationwide initiative to improve the accessibility of pulmonary rehabilitation[J].Chron Respir Dis,2017.[Epup ahead of print].
|
[7] |
Yoon HK,Park YB,Rhee CK,et al.Summary of the Chronic Obstructive Pulmonary Disease Clinical Practice Guideline revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease[J].Tuberc Respir Dis (Seoul),2017,80(3):230-240.
|
[8] |
陈淳,林建伟,任卓超等.布地奈德混悬液雾化吸入对慢性阻塞性肺疾病急性期肺功能及炎性因子的影响[J].中国现代医生,2017,55(25):1-3,7.
|
[9] |
禇岩.慢性阻塞性肺疾病合并呼吸衰竭的临床治疗方法研究[J].中国现代医生,2016,54(20):38-40.
|
[10] |
Lenferink A,Brusse-Keizer M,van der Valk PD,et al.Selfmanagement interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease[J].Cochrane Database Syst Rev,2017,8:CD011682.
|
[11] |
陈亚红,王辰.2015年更新版GOLD慢性阻塞性肺疾病诊断、治疗和预防的全球策略简介[J].中国医学前沿杂志(电子版),2015,7(2):34-39.
|
[12] |
陈学昂,李素云,王明航,等.影响慢性阻塞性肺疾病急性加重住院患者预后的因素分析[J].中华中医药学刊,2017,35(6):1358-1361.
|
[13] |
胡征宇,万国仕,袁建华,等.主肺动脉/降主动脉内径比值与COPD相关肺心病肺功能关系[J].浙江中西医结合杂志,2016,26(5):445-447.
|
[14] |
宋璐,徐丹,李风森.COPD发展“快”“慢”患者一年前后肺功能及相关炎性因子变化差异的研究[J].新疆医科大学学报,2015,38(6):745-747,753.
|
[15] |
钱航,周庆伟.中医特色疗法对COPD稳定期的治疗进展[J].中医研究,2013,26(9):77-80.
|
[16] |
狄红月,王志伟.中医康复治疗方案在COPD急性加重期的效果观察[J].天津中医药,2014,31(8):459-461.
|
[17] |
陶家虎.COPD稳定期的中医诊治[J].中医临床研究,2012,4(8):118-119.
|